Van ECK Associates Corp Acquires 273 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Van ECK Associates Corp lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 18.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,760 shares of the biopharmaceutical company’s stock after acquiring an additional 273 shares during the quarter. Van ECK Associates Corp’s holdings in Ultragenyx Pharmaceutical were worth $74,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in RARE. International Assets Investment Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 29,580.0% during the 3rd quarter. International Assets Investment Management LLC now owns 10,388 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 10,353 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Ultragenyx Pharmaceutical by 2.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 145,433 shares of the biopharmaceutical company’s stock worth $8,079,000 after acquiring an additional 3,259 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Ultragenyx Pharmaceutical by 34.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,333 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 851 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in Ultragenyx Pharmaceutical by 195.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 21,753 shares of the biopharmaceutical company’s stock worth $1,208,000 after purchasing an additional 14,394 shares during the last quarter. Finally, Pallas Capital Advisors LLC acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $598,000. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Trading Down 4.2 %

Shares of Ultragenyx Pharmaceutical stock opened at $42.59 on Monday. The business’s fifty day simple moving average is $43.15 and its 200 day simple moving average is $49.42. The firm has a market capitalization of $3.94 billion, a P/E ratio of -6.72 and a beta of 0.60. Ultragenyx Pharmaceutical Inc. has a 12 month low of $37.02 and a 12 month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm had revenue of $164.88 million during the quarter, compared to analysts’ expectations of $163.23 million. Analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Emil D. Kakkis sold 11,727 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the completion of the sale, the chief executive officer now owns 2,183,985 shares of the company’s stock, valued at approximately $92,229,686.55. This trade represents a 0.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on RARE. Wedbush reissued a “neutral” rating and set a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Wells Fargo & Company lifted their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, December 20th. HC Wainwright reissued a “buy” rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Piper Sandler boosted their price target on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, January 13th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $77.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $93.50.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.